Abstract
Purpose :
This study investigated the crucial aspect of selecting a suitable positive control in preclinical research, as exemplified by the comparative analysis of MediNect-identified MN007 and the established standard of care, Eylea (Aflibercept), within the subretinal fibrosis (SRF) model.
Methods :
Mice were subjected to three equidistant burns at the superior, nasal, and temporal aspects of the retina, followed by a second round of laser lesions after 7 days. The assessment of neovascularization and fibrosis was conducted at intervals of 7, 14, and 28 days post the second laser. OCT, Fluorescein Angiography (FA), and immunohistological staining (CD31 and alpha smooth muscle actin) were utilsed for assessment.
Results :
MN007 displayed a significantly superior therapeutic efficacy compared to Eylea through a reduction in fibrotic lesion volume (OCT) and neovascularisation (FA) at 7,14 and 28 days post laser (P<0.05). Protein expression of alpha-SMA and TGF-beta was significantly reduced at 28 days post laser (P<0.05). This study has shown a more efficacious compound, MN007, in the subretinal fibrosis model.
Conclusions :
These insights contribute to the refinement of experimental design, ensuring robust comparisons and meaningful translational implications in the evaluation of potential therapeutics for fibrosis and neovascularisation.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.